FDA Approves First Oral Antiviral to Block COVID-19 After Exposure
Ensitrelvir (Xocova) cuts COVID risk by more than half in exposed household contacts, offering a new post-exposure prevention tool.
Summary
The FDA has approved ensitrelvir (Xocova), an oral antiviral pill, to prevent COVID-19 in people aged 12 and older who have been recently exposed to the virus. Based on the phase III SCORPIO-PEP trial, the drug reduced infection risk by more than half compared to placebo when started within 72 hours of exposure. Only 2.9% of those taking ensitrelvir developed COVID versus 9% in the placebo group. The 5-day regimen is well tolerated, with adverse event rates nearly identical to placebo. This approval is particularly relevant for vulnerable populations in nursing homes, care facilities, and households with high-risk individuals.
Detailed Summary
The FDA has granted approval to ensitrelvir (Xocova), an oral antiviral developed by Shionogi, specifically for post-exposure prophylaxis (PEP) against COVID-19. This marks a meaningful shift in how exposed individuals — particularly those at higher risk — can protect themselves before symptoms ever develop.
The approval rests on data from the phase III SCORPIO-PEP trial, a rigorous randomized controlled study comparing ensitrelvir to placebo in household contacts of confirmed COVID-19 patients. In the modified intention-to-treat population, just 2.9% of ensitrelvir users developed COVID within 10 days versus 9% of placebo recipients — a reduction of more than half. In the full ITT population, rates were 4.4% versus 10.2%, both results reaching strong statistical significance (P<0.001).
Ensitrelvir works as a SARS-CoV-2 main protease inhibitor, blocking a key enzyme the virus needs to replicate. It is already approved in Japan both for treatment and prevention. In the U.S., it is approved only for PEP, not treatment. The drug must be initiated within 72 hours of exposure, with a loading dose of three 125-mg tablets on day one, followed by one tablet daily for four more days.
From a longevity and healthspan perspective, COVID-19 is increasingly recognized as a driver of long-term cardiovascular, neurological, and immune dysfunction. Preventing infection — not just treating it — is a meaningful strategy for reducing cumulative disease burden over a lifetime. This drug could be especially valuable in nursing homes, care facilities, and for immunocompromised individuals.
Important caveats apply: ensitrelvir should not be combined with CYP3A-metabolized drugs, and it carries fetal harm warnings. Long-term safety data beyond the trial window remain limited, and efficacy against future SARS-CoV-2 variants is not yet established.
Key Findings
- Ensitrelvir reduced COVID infection risk by more than half in exposed household contacts vs placebo.
- Only 2.9% of treated contacts developed COVID within 10 days versus 9% on placebo (P<0.001).
- Drug must be started within 72 hours of exposure; full course is 5 days oral dosing.
- Adverse event rates were nearly identical between ensitrelvir and placebo groups (15.1% vs 15.5%).
- Particularly useful in high-risk settings: nursing homes, care facilities, and immunocompromised individuals.
Methodology
This is a news report from MedPage Today summarizing an FDA approval and the supporting phase III SCORPIO-PEP randomized controlled trial. MedPage Today is a credible, physician-focused medical news outlet. The evidence basis is a phase III RCT with strong statistical significance across both ITT and modified ITT populations.
Study Limitations
The article does not report long-term follow-up data or outcomes beyond 10 days post-exposure. Efficacy against currently circulating or future SARS-CoV-2 variants is not addressed. Readers should consult the full SCORPIO-PEP trial publication and FDA prescribing information for complete safety and interaction data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.